Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Thermo Fisher Scientific, Marina, Alnylam, and More


Title: Vector

Patent Number: 8,501,466

Filed: Dec. 17, 2009

Lead Inventor: Venugopal Nair, Pirbright Institute

The invention, the patent’s abstract states, relates to a “herpes virus vector [comprising] a modified genomic sequence encoding a microRNA against a target sequence. The herpes virus vector may be used as or in a vaccine to prevent and/or treat a disease.”

Title: Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference

Patent Number: 8,501,706

Filed: July 19, 2012

Lead Inventor: Christina Yamada, Dharmacon (Thermo Fisher Scientific)

The invention comprises “duplex oligonucleotide complexes [that] can be administered to a cell, tissue, or organism to silence a target gene without the aid of a transfection reagent,” according to the patent’s abstract. “The duplex oligonucleotide complexes of the disclosure include a conjugate moiety that facilitates delivery to a cell, tissue, or organism.”

Title: Amino Acid Lipid and Uses Thereof

Patent Number: 8,501,824

Filed: March 30, 2011

Lead Inventor: Steven Quay, Marina Biotech

The patent, its abstract states, claims “a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.”

Title: Peptide-based In Vivo siRNA Delivery System

Patent Number: 8,501,930

Filed: Dec. 15, 2011

Lead Inventor: David Rozema, Arrowhead Research

The invention, the patent’s abstract states, “is directed compositions for targeted delivery of RNA interference polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.”

Title: Biodegradable Lipids for the Delivery of Active Agents

Application Number: 20130195920

Filed: Dec. 7, 2012

Lead Inventor: Martin Maier, Alnylam Pharmaceuticals

The invention, the patent application’s abstract states, relates to “a cationic lipid having one or more biodegradable groups located in a lipidic moiety of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.”

Title: Double-Stranded RNA Oligonucleotides [that] Inhibit Tyrosinase Expression

Application Number: 20130195966

Filed: March 11, 2013

Lead Inventor: Christine Collin-Djangone, L’Oreal

The invention comprises “novel double-stranded RNA oligonucleotides [that] are useful for decreasing tyrosinase expression, [and] have cosmetic and/or pharmaceutical applications,” the patent application’s abstract states.

Title: Method of Producing Dicer

Application Number: 20130196383

Filed: Aug. 2, 2012

Lead Inventor: Jennifer Doudna, University of California, Berkeley

The patent application, its abstract states, “provides a method for producing a Dicer polypeptide in a prokaryotic host cell … [as well as] a purified Dicer complex … [and] kits for producing a Dicer polypeptide in a prokaryotic host cell.”

Title: Enhancement of siRNA Silencing Activity using Universal Bases or Mismatches in the Sense Strand

Application Number: 20130196434

Filed: March 20, 2013

Lead Inventor: Martin Maier, Alnylam Pharmaceuticals

The invention relates to a “double-stranded nucleic acid … that has a sense strand and an antisense strand relative to a target nucleic acid, where the sense strand contains one or more modified nucleobases or one or more mismatch base pairings with the antisense strand,” according to the patent application’s abstract. “Another aspect of the … invention relates to a single-stranded oligonucleotide comprising at least one nucleoside comprising a non-natural nucleobase. Another aspect of the invention relates to a method of gene silencing, comprising administering to a mammal in need thereof a therapeutically effective amount of a double-stranded oligonucleotides containing a sense strand and an antisense strand, where the sense strand contains one or more modified nucleobases, or one or more mismatch base pairings with the antisense strand.”

Title: Inhibition of PCSK9 through RNAi

Application Number: 20130197055

Filed: Jan. 5, 2010

Lead Inventor: Joanne Kamens, RXi Pharmaceuticals

“The invention relates to various PCSK9 RNAi constructs with gene silencing activities and uses thereof,” the patent application’s abstract states. “The construct has a double-stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. The sense strand may be modified such that the construct is not cleaved by Dicer or … RNAse III, and the entire length of the antisense strand is loaded into RISC. In addition, the antisense strand may also be modified by 2'-O-methyl groups at the [second] 5'-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoid the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity.”

Title: microRNA Patterns for the Diagnosis, Prognosis, and Treatment of Melanoma

Application Number: 20130197060

Filed: Aug. 1, 2011

Lead Inventor: Gal Markel, Tel Aviv University

The invention, the patent application’s abstract states, relates to “methods for diagnosing, staging, prognosticating, and treating melanoma based on evaluating the expression of specific patterns of oncogenic or suppressive microRNA molecules in a patient in need thereof.”

Title: Agent for Suppressing Expression of Dominant Mutant Gene

Application Number: 20130197061

Filed: Sept. 28, 2011

Lead Inventor: Hirohiko Hohjoh, National Institute of Neuroscience, Japan

The invention comprises an “RNAi molecule that can selectively and effectively suppress only the expression of a particular dominant mutant gene, while permitting the expression of the wild-type gene or a desired mutant gene,” as well as a method of designing such a molecule, the patent application’s abstract states.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.